Boston Scientific and CryoCor, Inc. announced the signing of a definitive merger agreement to purchase CryoCor for approximately $17.6 million.

This acquisition follows a development agreement, in place since June 2007, to pursue therapeutic solutions for atrial fibrillation, or "Afib." Afib is the most common cardiac arrhythmia and affects millions of patients. The existing development agreement includes the development of a console to deliver cryo energy to Boston Scientific's proprietary cryo balloon catheter. This cryo balloon is being developed in order to provide a safe, standardized and broadly applicable way to isolate electrical activity originating from the pulmonary veins that are believed to be a source for the initiation and propagation of Afib.

According to Fred Colen, Executive Vice President, Operations and Technology, Boston Scientific Cardiac Rhythm Management, the acquisition will allow the company to further refine their base console technology, as well as gain exclusive rights to CryoCor's family of intellectual property that will provide key strategic advantages. He said is was a good example of Boston Scientific's Cardiac Rhythm Management and Electrophysiology teams working together to advance the most promising technologies and to potentially make new Afib solutions a reality for electrophysiologists and their patients.
Ed Brennan, Chief Executive Officer of CryoCor said that the company was pleased to see the cryoablation system and the intellectual property assets of CyroCor, Inc. partner with one of the world's leading electrophysiology companies.

About Boston Scientific Corporation

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Boston Scientific's Electrophysiology business is a leader in cardiac ablation products designed to treat common cardiac arrhythmias. Its line of Blazer(TM), Blazer XP(TM) and Chilli II(TM) products are used to treat arrhythmias such as Atrial Flutter and Ventricular Tachycardia. The Electrophysiology business also supplies a complete line of multi-electrode diagnostic catheters, ultrasound (ICE) catheters and accessories. The cryo balloon catheter is currently under development and not approved for sale.

About CryoCor, Inc.

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com.

Back to HCB News

More Industry Headlines